Allain J P, Zhai W, Shang D, Timmers E, Alexander G J
Department of Haematology, University of Cambridge, United Kingdom.
J Med Virol. 1999 Sep;59(1):25-31. doi: 10.1002/(sici)1096-9071(199909)59:1<25::aid-jmv5>3.0.co;2-j.
To investigate the potential clinical utility of antibody response to HVR1 of HCV, the genomic and amino acid diversity of HVR1 was compared between two groups of four chronic HCV carriers with or without liver cirrhosis. Peptides corresponding to the deduced COOH- and NH2-terminal amino acid sequences of HVR1 were synthesised to assess the reactivity of patient sera to autologous and homologous HVR1 epitopes by enzyme-linked immunosorbent assay. HCV chronic carriers had significantly more frequent cross-reactivity with homologous C- than N-terminal HVR1 peptides. Twelve cirrhotic and eleven noncirrhotic patients had a similar frequency of cross-reactivity with either C- or N-terminal HVR1 peptides. However, noncirrhotic patients had a significantly higher level of C-terminal HVR1 antibody cross-reactivity than cirrhotic patients. In HCV chronic carriers, the magnitude of the immune response to but not the frequency of cross-reactivity with C-terminus HVR1 peptides differ between patients with and without liver cirrhosis.
为研究丙型肝炎病毒（HCV）高变区1（HVR1）抗体反应的潜在临床应用价值，比较了两组各4名慢性HCV携带者（有无肝硬化）的HVR1基因和氨基酸多样性。合成了与HVR1推导的COOH端和NH2端氨基酸序列相对应的肽段，通过酶联免疫吸附试验评估患者血清对自身和同源HVR1表位的反应性。HCV慢性携带者与同源C端HVR1肽段的交叉反应明显比N端HVR1肽段更频繁。12例肝硬化患者和11例非肝硬化患者与C端或N端HVR1肽段的交叉反应频率相似。然而，非肝硬化患者C端HVR1抗体交叉反应水平明显高于肝硬化患者。在HCV慢性携带者中，有肝硬化和无肝硬化患者对C端HVR1肽段的免疫反应强度不同，但交叉反应频率无差异。
